Novartis study shows Zykadia reduces tumors in majority of ALK+ NSCLC patients
The company said that results were also observed in patients with ALK+ NSCLC who entered the trial with brain metastases. Seoul National University Hospital lead investigator Dong-Wan Kim
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.